Malik Fady Ibraham 4

What Happened

• Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), exercised and sold company shares on May 19, 2026. He exercised 3,500 option-derived shares at an exercise price of $7.80 (cost $27,300) and sold 3,500 shares in an open-market transaction at $75.69 each for proceeds of $264,915. The filing also reports a separate disposition of 3,500 derivative shares at $0.00 (see Key Details).

Key Details

• Transaction date: 2026-05-19; Filing date: 2026-05-20 (appears timely).
• Exercise: 3,500 shares @ $7.80 = $27,300 (transaction code M).
• Sale: 3,500 shares @ $75.69 = $264,915 (transaction code S).
• Additional derivative entry: 3,500 shares disposed @ $0.00 (transaction code M) — filing does not specify the reason.
• Shares owned after transaction: not specified in the Form 4.
• No 10b5-1 plan, tax-withholding statement, or other footnotes were specified in the filing.

Context

• This sequence (exercise followed by an immediate sale) is typically a cashless exercise where an insider converts options to stock and sells shares—resulting in net proceeds. The filing is a sale (liquidity event), which is common for covering exercise costs or taxes; it should not be interpreted as definitive insight into future company performance.